Closing on Nov. 3: Investor Calendar + Company Spotlight

INVESTOR NETWORK is the go-to, one-stop site for shareholders, clients and prospective investors

Teva Pharmaceutical Industries Ltd.

Teva Pharmaceutical Industries Ltd.

Sector: Generic Drugs Region: Israel

: | Tel Aviv Stock Exchange: TEVA | XETRA: TEV | New York Stock Exchange: TEVA

× We're Sorry! We do not have an investor kit available for this company. Tell us you want one!

Latest Media

Warning! Third-party cookies must be enabled to view SlideShare presentations. ×

Having trouble?

The Essential Piece

Convince each employee that he or she is an integral vital part of the whole at Teva

Teva Pharmaceutical Industries Ltd. video

The Essential Piece

Teva Pharmaceutical Industries Ltd. video

Teva Pharmaceutical Industries, Celebrates Transfer to New York Stock Exchange from NASDAQ

Teva Pharmaceutical Industries Ltd. video

Interview with Tony Martins, Vice President of Supply Chain at TEVA Pharmaceuticals


Dr. Jeremy M. Levin, President and Chief Executive Officer
Dr. Jeremy M. Levin, DPhil, MB, BChir, became President and Chief Executive Officer of Teva Pharmaceutical Industries Ltd. on May 9, 2012.
Prior to joining Teva, Dr. Levin was a member of the Senior Management Team at Bristol-Myers Squibb (BMS) , as Senior Vice President of Strategy, Alliances and Transactions. He was responsible for the company’s global and “String of Pearls” strategies, as well as M&A, licensing, divestitures, and corporate and academic alliances. At the same time, Dr. Levin served as President and Director of two wholly-owned BMS subsidiaries.
Before joining BMS, Dr. Levin served as the Global Head of Strategic Alliances at Novartis Institutes of Biomedical Research, where he managed alliances with academia and biotechnology, and established strategic collaborations. In addition, Dr. Levin has served on the executive committees and boards of numerous internationally renowned bioscience, biotechnology, venture fund and research organizations.
He holds a BA in Zoology from Oxford, and an MA and doctorate (DPhil) in Cell Biology and Chromatin Structure from the University of Oxford. He also holds an MB, BChir degree (Bachelor of Medicine, Bachelor of Surgery) from the University of Cambridge. He resides in Israel.
Eyal Desheh, Chief Financial Officer
Eyal Desheh became Chief Financial Officer in July 2008.
Mr. Desheh had previously served as Deputy Chief Financial Officer at Teva from 1989 to 1996.
From 2000 - until 2008, he was Executive Vice President and Chief Financial Officer of Check Point Software Technologies Ltd.
Mr. Desheh received a B.A. in economics in 1978 and an M.B.A. in finance in 1981, both from the Hebrew University.
Dr. Michael Hayden, President of Global R&D and Chief Scientific Officer
Dr. Hayden has international standing as a research scientist and clinician. He has an outstanding record of leadership, innovation, and is a clinician-scientist who has spent his entire working life in research that has led directly to medicines which have made a substantial difference to patients around the world. His work in genetics and personalized medicine is internationally renowned, and he is one of the world’s leading experts on Huntington’s disease.
Dr. Hayden also has extensive experience in all stages of medicine development – from target identification, through the complete cycle of clinical development, to submission and approval processes with regulators around the world.
Currently, he is Killam Professor of Medical Genetics at the University of British Columbia, and Canada Research Chair in Human Genetics and Molecular Medicine. He is also the founder and Director/Senior Scientist of the Centre for Molecular Medicine and Therapeutics at the University of British Columbia.
Dr. Hayden has founded three biotechnology companies: NeuroVir; Aspreva Pharmaceuticals; and Xenon Pharmaceuticals Inc. – where he is currently Chief Scientific Director. In 2011, he was awarded the Canada Gairdner Wightman award, recognizing him as a physician-scientist who has demonstrated outstanding leadership in medicine and medical science. In 2010, he was awarded the Order of Canada, which is the highest honour that Canada can give its citizens for exceptional achievement, merit or service.
In 2008 he was named Canada's Health Researcher of the Year and in 1998 received the Distinguished Scientist Award of the Canadian Society of Clinical Investigation. These are just some of the array of major honors and awards that demonstrate the esteem in which he is held internationally.

News & Analysis

You may also be interested in: